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Risk factors associated with the deterioration of renal func-
tion after kidney transplantation. Renal function early after
transplantation is associated with a large number of risk fac-
tors, including donor age and acute rejection. During the 1990s,
donor age increased and the incidence of acute rejection de-
creased. Renal function between the third and sixth month
improved slightly, while renal function deterioration between
the third or sixth month and the 12th month improved sig-
nificantly. This modification coincides with the introduction of
mycophenolate mofetil and tacrolimus. The tendency for sus-
tained renal improvement early after transplantation became
more evident after the introduction of anti-calcineurin–free reg-
imens. Studies of protocol biopsies have shown that there is an
increase of glomerular volume after transplantation and that
a larger glomerular volume at 4 months is associated with a
better glomerular filtration rate. This adaptation mechanism is
impaired in patients with chronic allograft nephropathy or in pa-
tients with high cyclosporin levels. Taken together, these data
suggest that the steady improvement of renal allograft function
may be partly explained by a better glomerular adaptation after
transplantation because of the avoidance of the vasoconstric-
tive effect of anti-calcineurinic agents, and a significant decrease
in the prevalence of chronic allograft nephropathy early after
transplantation.
Epidemiologic studies have shown that renal allograft
survival is associated with a large number of risk factors,
such as donor or recipient age, sex, and race, or comor-
bid conditions, type of donor (living vs. cadaver), cause of
donor death (stroke vs. trauma), panel reactivity antibod-
ies, and the presence of delayed graft function or acute
rejection. However, one of the most powerful predictors
of graft outcome is renal allograft function. Moreover,
renal function is also a major determinant of patient sur-
vival [1, 2]. Thus, it has been suggested that strategies
to improve renal function after transplantation may con-
tribute to increased patient and allograft survival.
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PREDICTIVE VALUE OF RENAL FUNCTION ON
PATIENT AND GRAFT SURVIVAL
The gold standard to measure renal function is the
glomerular filtration rate (GFR), evaluated according
to the inulin clearance or an isotopic method. Because
these procedures cannot be applied in the clinical set-
ting because of their cost and complexity, different for-
mulas have been developed to estimate GFR that take
into account clinical and analytical parameters. However,
the agreement between predicted and measured GFR is
rather low. It has been recently shown that the proportion
of predicted GFR differing from inulin clearance by ±
10 mL/min/1.73 m2 ranged from 34% to 53% depending
on the formula applied [3]. These results suggest that es-
timated GFR cannot substitute the determination of real
GFR, at least in clinical trials. A second consequence of
these observations is that the predictive value of renal al-
lograft function on graft or patient outcome has probably
been underestimated in epidemiologic studies.
One strategy to improve the predictive value of renal
function on graft and patient outcome is to separate the
evolution of renal function into two parameters: serum
creatinine (SCr) or estimated GFR at 3 or 6 months,
which roughly represents the early adaptation of the re-
nal allograft after transplantation, and the evolution of
renal function between this early period and the 12th
month, the so-called dSCr or dGFR, which represents
the risk for further renal allograft deterioration [1, 4].
This strategy is based on the observation that there is a
very weak correlation between SCr or estimated GFR
early after transplantation and dSCr or dGFR. For exam-
ple, Gourishankar et al [5] did not find any association
between 6-month GFR and the slope of GFR after the
sixth month in a study including 429 cadaver renal re-
cipients transplanted at a single center. In a multicenter
study performed in Spain that included 3365 patients who
received a single kidney in 1990, 1994, and 1998 that was
functioning at the end of the first year [2], the correlation
between SCr at 3 months and dSCr was weak despite
being significant (r2 = 0.099). Similarly, when GFR was
estimated by means of the Cockroft-Gault formula, the
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correlation between GFR at 3 months and dGFR did not
improve (r2 = 0.108). Thus, it is not surprising that both
the SCr and dSCr or GFR and dGFR parameters are
independent predictors of patient and allograft survival
[1, 2].
FACTORS ASSOCIATED WITH SCR AND dSCR
Renal function during the first year is associated with
different risk factors. In the Spanish Study of Chronic
Allograft Nephropathy, the following covariates were as-
sociated with an increased SCr at 3 months: older donor
age, female donor sex, stroke as a cause of donor death,
male recipient sex, cold ischemia time, the presence of
delayed graft function, acute rejection, cytomegalovirus
infection, and re-intervention for any reason. However,
only two factors were associated with dSCr deterioration
between the third and 12th month: acute rejection and re-
cipient hepatitis C virus antibodies [4]. These data show
that acute rejection is not only associated with an irre-
versible decline of renal function early after transplanta-
tion, but also with an accelerated renal allograft function
deterioration, probably reflecting that acute rejection
triggers immune mechanisms that continue to harm the
kidney, far beyond the apparent resolution of the acute
rejection episode. These data also indicate the impor-
tance of hepatitis C virus infection that contributes to
renal function deterioration because of sustained renal
allograft immune-mediated damage. It is important to
note that these two covariates were also major indepen-
dent predictors of death-censored allograft survival.
In a study that included 85,135 patients from the Or-
gan Procurement and Transplantation Network/United
Network for Organ Sharing with a functioning graft at
the end of the first year, risk factors associated with
SCr >1.5 mg/dL were evaluated and compared with risk
factors associated with renal allograft survival. The fol-
lowing covariates were associated with elevated serum
creatinine at 1 year, graft survival, and death-censored
graft survival: older donor age, black donor race, younger
recipient age, black recipient race, male recipient sex, de-
layed graft function, and the presence of acute rejection.
Because risk factors for 1-year renal allograft dysfunction
and graft failure were similar, the possible utility of 1-year
SCr as a surrogate marker of renal allograft outcome was
suggested [6]. However, when power calculations were
performed to calculate minimum sample size in a hypo-
thetical trial in which 1-year serum creatinine could be
considered the primary efficacy variable, the sample size
was rather large, raising doubts about the utility of serum
creatinine at 1 year as a useful end point [7].
EVOLUTION OF RENAL FUNCTION AFTER
TRANSPLANTATION SINCE 1990
There is some discrepancy in the studies describing how
renal function has evolved in recent years in transplanted
patients. In the United States, 1-year SCr steadily im-
proved between 1988 and 1998 from 1.82 ± 0.82 mg/dL
to 1.67 ± 0.82 mg/dL [1]. In a study describing the evo-
lution of 6-month GFR between 1991 and 2000, the im-
provement of 6-month GFR occurred during a discrete
period of time, ranging between 1994 and 1997. Before
and after this period, GFR remained stable, and this im-
provement coincided with the introduction of mycophe-
nolate mofetil and tacrolimus [8]. Gourishankar et al
have observed that, although 6-month creatinine clear-
ance remained stable between 1990 and 2000, the slope
of the creatinine clearance after the sixth month im-
proved. The kidneys that were transplanted before 1997
significantly deteriorated over time. For the period from
1990 to 1993, the mean creatinine clearance slope was
−0.34 mL/min/month, and for the period from 1994 to
1997, it was −0.20 mL/min/month. In contrast, mean GFR
slope improved by +0.29 mL/min/month during the pe-
riod from 1998 to 2000.
In Spain, SCr at 3 months has been slightly modified
during the last decade. The lowest SCr was observed in
1990 (1.59 ± 0.64 lmol/L), the highest in 1994 (1.72 ±
0.73 lmol/L), and an intermediate value was observed
in 1998 (1.65 ± 0.66 lmol/L). However, while dGFR be-
tween the third and 12th month deteriorated −0.8 mL/
min/1.73 m2 in 1990 and −0.4 mL/min/1.73 m2 in 1994, it
improved 1.0 mL/min/1.73 m2 in 1998. Again, in 1990 and
1994, the use of mycophenolate mofetil and tacrolimus
was negligible in Spain. However, despite raising opti-
mistic expectations [1], these tendencies for better renal
function preservation have not been associated with any
important modification of long-term renal allograft sur-
vival [9]. During the 1990s, important modifications in
donor and recipient characteristics occurred. While acute
rejection was reduced, donor quality worsened and re-
cipient age increased. These modifications may offset the
beneficial effects of new treatments for graft outcome [1,
2, 8].
IMMUNOSUPPRESSIVE TREATMENT AND
RENAL FUNCTION
Since the introduction of mycophenolate mofetil and
tacrolimus, dGFR has significantly improved [4, 5, 8,
10]. It has been suggested that this improvement is re-
lated to the superior immunosuppressive activity of these
drugs that allow a reduction in the incidence of not
only acute rejection [11, 12], but also subclinical rejec-
tion [13, 14]. Furthermore, it has been suggested that
both treatments may decrease the rate of progression of
chronic allograft nephropathy (CAN) [13, 15, 16]. This
tendency for a better preservation of renal function be-
came more evident after the introduction of sirolimus. In
a prospective, randomized study evaluating cyclosporin
(CsA) withdrawal at 3 months from sirolimus treatment,
CsA, and a steroid-based regimen, it was observed that
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renal function steadily improved in patients in the CsA
withdrawal group, while renal function deteriorated in
patients on CsA and sirolimus. At 36 months, estimated
GFR was 47 mL/min/1.73 m2 in patients on CsA and
59 mL/min/1.73 m2 in patients without CsA [17]. Simi-
larly, in a prospective randomized trial comparing an anti-
calcineurin inhibitor (anti-CNI)–free regimen based on
sirolimus, mycophenolate mofetil, and prednisone with
an anti-CNI–based regimen consisting of CsA, mycophe-
nolate mofetil (MMF), and prednisone, renal function
steadily increased during the first 36 months in the anti-
CNI–free group, while it steadily deteriorated in patients
in the CNI-based regimen [18]. These data indicate the
contribution of anti-CNI toxicity in progressive renal al-
lograft function deterioration.
CORRELATION BETWEEN RENAL FUNCTION
AND HISTOLOGIC LESIONS
In stable renal allografts, it has been observed that
the correlation between structure and function is much
weaker than expected. For example, in a study in which
a protocol biopsy was done at 3 months, serum creati-
nine was 125 ± 35 lmol/L in patients without CAN and
145 ± 35 lmol/L in patients with CAN (P = 0.008). De-
spite this difference, it was observed that the predictive
value of CAN on graft survival was independent of either
graft function or proteinuria, suggesting that histology
evaluated early after transplantation contains relevant in-
formation to predict graft survival that is different from
the information contained in surrogate variables of renal
function [19]. This observation was confirmed in a larger
study [20].
The notion that there is a poor correlation between
structure and function in stable grafts is further rein-
forced by a study that included 32 CsA-treated patients
with serum creatinine <200 lmol/L and proteinuria <1 g/
24 hours, in whom a protocol biopsy was done at 5 months.
In these patients, renal function was measured with inulin
clearance. Additionally, effective renal plasma flow, re-
nal functional reserve after amino acid infusion and after
simultaneous amino acid, and dopamine infusion were
determined. When patients were classified according to
the presence or absence of CAN, no differences were ob-
served between both groups [21]. Furthermore, in a study
of serial protocol biopsies performed at 4 and 14 months,
chronic lesions significantly progressed in the different re-
nal compartments, while SCr remained stable [22]. Taken
together, these data suggest that renal function does not
properly reflect structural damage early after transplan-
tation, at least when biopsies are evaluated according to
Banff criteria, and raise the question of whether more
precise evaluation of renal structural damage may allow
a better understanding of the relationship between struc-
ture and function in stable grafts.
RELATIONSHIP BETWEEN GLOMERULAR
NUMBER, GLOMERULAR VOLUME, AND
RENAL FUNCTION IN STABLE GRAFTS
Studies performed on autopsy specimens have shown
that glomerular number in patients without a history
of renal disease shows a great variability, ranging ap-
proximately between 200,000 and 1,800,000 [23, 24]. In
these studies, an inverse relationship between glomeru-
lar number and glomerular volume has been described,
suggesting that glomerular enlargement represents an
adaptation mechanism to provide normal patients with
a sufficient filtration surface area and, accordingly, it may
be considered a rough surrogate measure of glomeru-
lar number [24]. Aging is associated with decreased
glomerular number and increased glomerular volume;
moreover, susceptibility to renal disease is associated
with low glomerular endowment [25–27]. Similarly, in
renal transplants, larger glomerular size evaluated in
donor biopsies is associated with late renal allograft dys-
function [28]. In epidemiologic studies, surrogate mea-
sures of transplanted renal mass are associated with
decreased allograft survival [29], and in an experimental
setting, transplanted renal mass is a major determinant
of graft survival [30]. These data suggest that estimation
of glomerular number in renal allografts may be useful
to better characterize the relationship between structure
and function in patients with transplants.
Because the gold standard method of counting glo-
meruli can only be applied in autopsy studies, glomerular
number can be estimated in vivo only if the following
parameters are known: mean glomerular volume, cor-
tical glomerular volume fraction, and the absolute vol-
ume of renal cortex [31]. The first two parameters can
be estimated in a renal biopsy applying a morphometric
technique, and the second can be obtained with magnetic
resonance imaging. This approach has been applied to es-
timate glomerular number in stable grafts at 4 months to
better characterize anatomo-clinical correlations. A total
of 39 patients with a serum creatinine <200 lmol/L and
proteinuria <1 g/24 hours were included. A few days af-
ter the protocol biopsy, inulin clearance was determined
and renal magnetic resonance imaging was performed.
The mean glomerular number was 0.73 ± 0.33 × 106
(range, 0.21-1.66). Mean GFR was 56 ± 15 mL/min/1.73
m2 (range, 39-79). There was an association between
glomerular number and GFR (r = 0.47, P = 0.002), show-
ing that the number of transplanted glomeruli is a major
determinant of renal function after transplantation.
GLOMERULAR ADAPTATION AFTER RENAL
TRANSPLANTATION
Glomerular adaptation to body growth during child-
hood or adaptation after renal ablation is characterized
by glomerular enlargement. Renal transplants receive
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only half the glomerular number. After transplantation,
the kidney is exposed to different insults such as ischemia-
reperfusion injury, acute rejection, and drug nephrotoxi-
city, which may reduce the capacity of glomeruli to adapt
to the recipient metabolic demand. To evaluate glomeru-
lar adaptation after transplantation, Vg (glomerular vol-
ume) has been measured in paired donor and 4-month
protocol biopsies [32]. It was observed that glomeruli en-
large during this early period from 4.1 ± 1.4 × 106 lm3 to
5.1 ± 2.4 × 106 lm3. Furthermore, a positive association
between glomerular size at 4 months and estimated GFR
according to the Cockroft-Gault formula (r = 0.38, P =
0.01) was described, suggesting that glomerular adapta-
tion is a necessary condition to achieve a better renal func-
tion early after transplantation. Interestingly, glomerular
enlargement was observed in patients without chronic le-
sions in the protocol biopsy, but not in patients displaying
CAN.
The long-term consequences of this adaptation pro-
cess have not been characterized. Despite graft function
as a determinant of graft survival, there is a size thresh-
old for glomerular enlargement that leads to glomeru-
losclerosis and progressive renal failure, which has to be
taken into consideration [33]. To evaluate the relative
contribution of renal function and glomerular volume on
graft survival in stable grafts, we evaluated 144 patients
in whom an early protocol biopsy with sufficient tissue
was available. Patients were divided into four groups ac-
cording to glomerular volume and renal function. The
outcome was excellent in patients with small glomeruli
(<5 × 106 lm3) and good renal function (estimated GFR
>60 mL/min/1.73 m2) and was the poorest in patients with
large glomeruli and poor renal function. Graft survival
was intermediate in the other two groups (unpublished
observation). We interpreted this to mean that recipi-
ents with small glomerular volume and good renal func-
tion may represent patients endowed with a large number
of glomeruli and, accordingly, the filtration surface area
was sufficient to provide an adequate renal function. In
contrast, recipients with large glomeruli and poor renal
function may represent those patients who, despite adap-
tation, had insufficient filtration surface area to provide
an adequate renal function. However, we were intrigued
with the group of patients with small glomeruli and poor
renal function. This situation suggested that their capac-
ity to adapt after transplantation was impeded. When the
four groups were compared, CsA exposure was higher
in patients with poor renal function and small glomeruli.
These data suggest that CsA prevents glomerular adap-
tation to recipient metabolic demand.
CONCLUSION
Glomerular enlargement is associated with better re-
nal function after transplantation. This adaptation mech-
anism does not occur in patients already displaying CAN
or in patients with high CsA exposure. In the last decade,
a steady increase of dGFR after the third month has been
observed. This modification was first described after the
introduction of mycophenolate mofetil and tacrolimus,
which prevent nephrotoxicity and decrease the incidence
of CAN. However, after the introduction of calcineurin-
free regimens based on sirolimus, this effect has become
more evident. Thus, we may speculate that the steady
increase of renal function observed in the last decade
may be partly explained by a better glomerular adap-
tation after transplantation due to the avoidance of the
vasoconstrictive effect of anti-calcineurinic agents and a
significant decrease in the prevalence of CAN early after
transplantation.
ACKNOWLEDGMENT
This work was supported by FIS grants (PI040164) and (PI040086)
and a Sociedad Espan˜ola de Nefrologı´a (SEN 2004) grant.
Reprint requests to Prof. Daniel Sero´n, Nephrology Department, Hos-
pital Universitari de Bellvitge, c./Feixa Llarga s/n, L’Hospitalet 08907,
Barcelona, Spain.
E-mail: 17664dsm@comb.es
REFERENCES
1. HARIHARN S, MCBRIDE MA, CHERIKH WS, et al: Post-transplant re-
nal function in the first year predicts long term-renal kidney trans-
plant survival. Kidney Int 62:311–318, 2002
2. SERO´N D, ARIAS M, CAMPISTOL JM, MORALES JM FOR THE SPANISH
CHRONIC ALLOGRAFT NEPHROPATHY STUDY GROUP: Late renal allo-
graft failure between 1990 and 1998 in Spain: a changing scenario.
Transplantation 76:1588–1594, 2003
3. MARIAT C, ALAMARTINE E, BATHELEMY JC, et al: Assessing renal
graft function in clinical trials: Can tests predicting glomerular fil-
tration rate substitute for a referred method? Kidney Int 65:289–297,
2004
4. SERO´N D, GO´MEZ-ULLATE P, GUTIERREZ-COLO´N JA, et al: Early post-
transplant renal allograft function between 1990 and 1998 in Spain.
Nephrol Dial Transplant 19(Suppl 3):S43–S46, 2004
5. GOURISHANKAR S, HUNSICKER LG, JHANGRI GS, et al: The stability of
the glomerular filtration rate after renal transplantation is improv-
ing. J Am Soc Nephro 14:2387–2394, 2003
6. SIDDIQI N, MCBRIDE MA, HARIHARAN S: Similar risk profiles
for post-transplant renal dysfunction and long term graft fail-
ure: UNOS/OPTN database analysis. Kidney Int 65:1906–1913,
2004
7. HARIHARAN S, MC BRIDE M, COHEN EP: Evolution of endpoints for
renal transplant outcome. Am J Transplant 3:933–941, 2003
8. KEITH DS, DEMATTOS A, GOLCONDA M, et al: Factors associated
with improvement in deceased donor renal allograft function in the
1990s. J Am Soc Nephrol 16:1512–1521, 2005
9. MEIER-KRIESCHE HU, SCHOLD JD, KAPLAN B: Long term renal al-
lograft survival: Have we made significant progress or is it time to
rethink our analytic and therapeutic strategies. Am J Transplant
4:1289–1295, 2004
10. GILL JS, TONELLI M, MIX CH, et al: The effect of maintenance
immunosuppression medication on the change in kidney allograft
function. Kidney Int 65:692–699, 2004
11. EUROPEAN MYCOPHENOLATE MOFETIL COOPERATIVE STUDY GROUP:
Placebo-controlled study of mycophenolate mofetil combined with
cyclosporine and corticosteroids for prevention of acute rejection.
Lancet 345:1321–1325, 1995
12. MARGREITER R FOR THE EUROPEAN TACROLIMUS VS. CYCLOSPORIN
MICROEMULSION RENAL TRANSPLANTATION STUDY GROUP: Efficacy
Sero´n et al: Renal function in kidney transplants S-117
and safety of tacrolimus compared with cyclosporin microemulsion
in renal transplantation: A randomised multicentre study. Lancet
359:741–746, 2002
13. NANKIVELL BJ, BORROWS RJ, FUNG CL, et al: The natural history
of chronic allograft nephropathy. N Engl J Med 349:2326–2333,
2003
14. MORESO F, SERO´N D, CARRERA M, et al: Baseline immunosuppres-
sion is associated with histological findings in early protocol biopsies.
Transplantation 78:1064–1068, 2004
15. OJO AO, MEIER-KRIESCHE HU, HANSON J, et al: Mycophenolate
mofetil reduces late renal allograft loss independent of acute re-
jection. Transplantation 69:2405–2409, 2000
16. GONZALEZ-MOLINA M, SERO´N D, GARCIA DEL MORL R, et al: My-
cophenolate mofetil reduces deterioration of renal function in pa-
tients with chronic allograft nephropathy. Transplantation 77:215–
220, 2004
17. KREIS H, OBERBAUER R, CAMPISTOL JM, et al: Long-term benefits
with sirolimus-based therapy after early cyclosporine withdrawal. J
Am Soc Nephrol 15:809–817, 2004
18. FLECHNER SM, KURIAN SM, SOLEZ K, et al: De novo kidney transplan-
tation without use of calcineurin inhibitors preserves renal structure
and function at two years. Am J Transplant 4:1776–1785, 2004
19. SERO´N D, MORESO F, BOVER J, et al: Early protocol renal allograft
biopsies and graft outcome. Kidney Int 51:310–316, 1997
20. SERO´N D, MORESO F, RAMO´N JM, et al: Protocol renal allograft biop-
sies and the design of clinical trials aimed to prevent or treat chronic
allograft nephropathy. Transplantation 69:1849–1855, 2000
21. FULLADOSA X, MORESO F, TORRAS J, et al: Structural and functional
correlations in stable renal allografts. Am J Kidney Dis 41:1065–
1073, 2003
22. MORESO F, LOPEZ M, VALLEJOS A, et al: Serial protocol biopsies to
quantify the progression of chronic transplant nephropathy in stable
grafts. Am J Transplant 1:82–88, 2001
23. NYENGAARD JR, BENDTSEN TF: Glomerular number and size in re-
lation to age, kidney weight and body surface area in normal man.
Anat Rec 232:194–201, 1992
24. HOY WE, DOUGLAS-DENTON RN, HUGHSON MD, et al: A stereolog-
ical study of glomerular number and volume: Preliminary findings
in a multiracial study of kidneys at autopsy. Kidney Int 63(Suppl
83):S31–S37, 2003
25. BARKER DJ, OSMOND C, GOLDING J, et al: Growth in utero, blood
pressure in childhood and adult life and mortality from cardiovas-
cular disease. Br Med J 298:564–567, 1989
26. KELLER G, ZIMMER G, MALL G, et al: Nephron number in patients
with primary hypertension. N Engl J Med 348:101–108, 2003
27. BRENNER BM, MILFORD L: Nephron underdosing: A programmed
cause of chronic renal allograft failure. Am J Kidney Dis 21:66–72,
1993
28. ABDI R, SLAKEY D, KITTUR D, et al: Baseline glomerular size as a
predictor of function in human renal transplantation. Transplanta-
tion 66:329–333, 1998
29. TERASAKI PI, GJERTSON DW, CECKA JM, TAKEMOTO S: Fit and match
hypothesis for kidney transplantation. Transplantation 62:441–445,
1996
30. CRUZADO JM, TORRAS J, RIERA M, et al: Influence of nephron mass
in development of chronic renal failure after prolonged warm renal
ischaemia. Am J Physiol Renal Physiol 279:F259–F269, 2000
31. BASGEN JM, STEFFES MW, STILLMAN AE, MAUER SM: Estimating
glomerular number in situ using magnetic resonance imaging and
biopsy. Kidney Int 45:1668–1672, 1994
32. ALPEROVICH G, MALDONADO R, MORESO F, et al: Glomerular en-
largement assessed by paired donor and early protocol renal allo-
graft biopsies. Am J Transplant 4:650–654, 2004
33. BATHENA DB: Glomerular size and the association of focal glomeru-
losclerosis in long-surviving human renal allografts. J Am Soc
Nephrol 4:1316–1326, 1993
